Dr Suchitra Sundaram shares key highlights on frontline time limited and all oral regimens producing deep MRD responses, ...

For those and other reasons, targeted oral therapies like Bruton tyrosine kinase inhibitors (BTKis) and the BCL-2 inhibitor ...

In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

The aim of the fixed-duration approach is to "produce deep remissions and thereby allow patients to get off therapy while ...

Zanubrutinib and venetoclax combination shows an 87% 36-month PFS rate in CLL/SLL patients, regardless of del (17p)/TP53 or IGHV status. The SEQUOIA trial demonstrates durable minimal residual disease ...

Bruton’s tyrosine kinase inhibitors such as ibrutinib have significantly improved outcomes for chronic lymphocytic leukemia, ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

Detailed price information for Adaptive Biotechnologies Corp (ADPT-Q) from The Globe and Mail including charting and trades.

ORLANDO -- In a phase III trial with potential practice-changing implications, the non-covalent Bruton's tyrosine kinase (BTK ...